Table 1.
Rituximab-based salvage therapy in relapsing/refractory DLBCL
NS indicates not significant.
*Plus RIT at bulky disease.
†The choice of conditioning regimen depended on physician decision and the clinical trial.
Rituximab-based salvage therapy in relapsing/refractory DLBCL
NS indicates not significant.
*Plus RIT at bulky disease.
†The choice of conditioning regimen depended on physician decision and the clinical trial.
